Edition:
United States

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

23.72USD
3:59pm EST
Change (% chg)

$0.79 (+3.45%)
Prev Close
$22.93
Open
$22.91
Day's High
$23.73
Day's Low
$22.84
Volume
189,651
Avg. Vol
221,587
52-wk High
$37.80
52-wk Low
$21.31

Chart for

About

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is... (more)

Overall

Beta: --
Market Cap(Mil.): $1,281.57
Shares Outstanding(Mil.): 50.54
Dividend: --
Yield (%): --

Financials

  AIMT.OQ Industry Sector
P/E (TTM): -- 30.48 33.70
EPS (TTM): -2.24 -- --
ROI: -50.47 14.95 14.45
ROE: -50.82 16.27 15.96

BRIEF-Aimmune Therapeutics Announces Closing Of $98 Mln Investment By Nestlé Health Science

* AIMMUNE THERAPEUTICS ANNOUNCES CLOSING OF $98 MILLION INVESTMENT BY NESTLÉ HEALTH SCIENCE

Nov 28 2018

Nestle raises stake in food allergy drug developer Aimmune

The health science arm of Nestle SA will pay $98 million to raise its stake in Aimmune Therapeutics Inc, the drug developer said, as it prepares to submit a marketing application for its peanut allergy drug by the end of the year.

Nov 12 2018

UPDATE 2-Nestle raises stake in food allergy drug developer Aimmune

Nov 12 The health science arm of Nestle SA will pay $98 million to raise its stake in Aimmune Therapeutics Inc, the drug developer said, as it prepares to submit a marketing application for its peanut allergy drug by the end of the year.

Nov 12 2018

BRIEF-Aimmune Therapeutics Announces Additional Equity Investment By Nestlé Health Science

* AIMMUNE THERAPEUTICS ANNOUNCES ADDITIONAL EQUITY INVESTMENT BY NESTLÉ HEALTH SCIENCE

Nov 12 2018

Nestle raises stake in food allergy drug developer Aimmune

Nov 12 The health science unit of Nestle SA would pay $98 million to increase its stake in Aimmune Therapeutics Inc, the drug developer for food allergies said on Monday.

Nov 12 2018

Earnings vs. Estimates